In Massachusetts, Xenetic Biosciences, Inc. has a new Chief Scientific Officer, Curtis A. Lockshin. Lockshin’s experience with research and development in the biopharmaceutical industry and his various biomaterials, therapeutics and biosensors inventions and patents will come in handy in his new role at Xenetic, a biopharmaceutical company. Lockshin was formerly a CEO, or served in other executive roles, at SciVac Therapuetics, VBI Vaccines, Guardum Pharmaceuticals, and OPKO Health. Lockshin will help Xenetic with their focus on next-gen biologic drugs and oncology therapeutics. Scott Maguire, Chief Executive Officer of Xenetic said in their press release “With our second important executive level appointment since our Nasdaq listing, Xenetic now has a structure to deliver on what we believe will be a transformational 2017.”
Latest article
Bioplastic could make drink spiking a thing of the past
In Canada, researchers at the University of British Columbia have invented a drink stirrer with a bioplastic tip that can detect whether a drink...
Nestlé gives cheese packaging a cheesy origin story
In Panama, food and beverage multinational Nestlé and advertising firm Ogilvy Colombia have introduced a biodegradable cheese wrapper made from whey, a cheesemaking byproduct....
Construction of AgroRenew bioplastics plant may be delayed due to tariffs
In Indiana, bioplastics producer AgroRenew has told WIBQ that its previously announced production plant in Vincennes could be delayed due to tariffs. The company said...